Serum neurofilament light chain (sNfL) levels in MS are associated with inflammatory activity and less clearly with disability. In this touchNEUROLOGY interview, we caught up with Dr Georgina Arrambide (Cemcat, Vall d´Hebron University Hospital, Barcelona, Spain) to discuss the findings from a study investigating sNfL Z score cut-offs in MS, and the impact on diagnosis specificity and predicting disability milestones.
The abstract entitled ‘Predictive sNfL Z score cut-offs in MS vary depending on the outcome and may help increase diagnostic specificity at the expense of sensitivity in CIS patients not fulfilling McDonald MS at baseline’ (Abstract #O177) was presented at ECTRIMS, 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 26 – 28 October 2022, Amsterdam, the Netherlands.
Questions:
- What is known about the significance of serum neurofilament light chain (sNFL) levels in MS? (0:17)
- What were the aims, methodology and patient population of your study? (0:46)
- What were the findings of the study in terms of diagnosis specificity and predicting disability milestones? (2:47)
- What questions remained unanswered and what future studies are planned? (4:22)
Disclosures: Georgina Arrambide receives grant/research support from Instituto de Salud Carlos III (FIS PI19/01570); is on the advisory board for Horizon Therapeutics, Roche, Sanofi and Merck; and receives honoraria/honorarium from Novartis, Roche, and ECTRIMS.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ECTRIMS 2022
